Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death

Journal of Neurochemistry

Volumn 103, Issue 2, 2007, Pages 518-530

  Monti, Barbara ^a   Polazzi, Elisabetta ^a   Batti, Laura ^a   Crochemore, Christophe ^a   Virgili, Marco ^a   Contestabile, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

6 hydroxydopamine; Alpha synuclein; Oligonucleotide antisense; Parkinson's disease; Primary neuronal cultures; Valproic acid

Indexed keywords

ALPHA SYNUCLEIN; ANTISENSE OLIGONUCLEOTIDE; OXIDOPAMINE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL VIABILITY; CEREBELLAR GRANULE NEURON; CONTROLLED STUDY; DISEASE MODEL; MALE; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SYNAPTIC TRANSMISSION; UBIQUITINATION;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; CEREBELLUM; CYTOPLASMIC GRANULES; CYTOSOL; GENE SILENCING; IMMUNOPRECIPITATION; MALE; NEURONS; NEUROPROTECTIVE AGENTS; OLIGONUCLEOTIDES, ANTISENSE; OXIDOPAMINE; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYMPATHOLYTICS; TRANSLOCATION, GENETIC; VALPROIC ACID;

EID: 34848881102     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04778.x     Document Type: Article

References (82)

1. Abad F., Maroto R., Lopez M. G., Sanchez-Garcia P. Garcia A. G. (1995) Pharmacological protection against the cytotoxicity induced by 6-hydroxydopamine and H2O2 in chromaffin cells. Eur. J. Pharmacol. 293, 55 64.
2. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239 252.
3. Adamczyk A., Solecka J., Strosznajde J. B. (2005) Expression of alpha-synuclein in different brain parts of adult and aged rats. J. Physiol. Pharmacol. 56, 29 37.
4. Andrew R., Watson D. G., Best S. A., Midgley J. M., Wenlong H. Petty R. K. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18, 1175 1177.
5. Baba Y., Markopoulou K., Putzke J. D., Whaley N. R., Farrer M. J., Wszolek Z. K. Uitti R. J. (2006) Phenotypic commonalities in familial and sporadic Parkinson disease. Arch. Neurol. 63, 579 583.
6. Barzilai A. Melamed E. (2003) Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol. Med. 9, 126 132.
7. Betarbet R., Canet-Aviles R. M., Sherer T. B. et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404 420.
8. Blum D., Torch S., Lambeng N., Nissou M., Benabid A. L., Sadoul R. Verna J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135 172.
9. Bove J., Prou D., Perier C. Przedborski S. (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2, 484 494.
10. Cabin D. E., Shimazu K., Murphy D. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797 8807.
11. Caruccio L. Banerjee R. (1999) An efficient method for simultaneous isolation of biologically active transcription factors and DNA. J. Immunol. Meth. 230, 1 10.
12. Choi H. S., Lee S. H., Kim S. Y. et al. (2006) Transduced Tat-alpha-synuclein protects against oxidative stress in vitro and in vivo. J. Biochem. Mol. Biol. 39, 253 262.
13. Clayton D. F. George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249 254.
14. Clayton D. F. George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120 129.
15. Cohen G. Heikkila R. E. (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249, 2447 2452.
16. Contestabile A. (2002) Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro. Cerebellum 1, 41 55.
17. Conway K. A., Harper J. D. Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318 1320.
18. Cookson M. R., Xiromerisiou G. Singleton A. (2005) How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr. Opin. Neurol. 18, 706 711.
19. da Costa C. A., Ancolio K. Checler F. (2000) Wild-type but not Parkinson's disease-related ala-53→Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065 24069.
20. da Costa C. A., Masliah E. Checler F. (2003) Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J. Biol. Chem. 278, 37330 37335.
21. da Costa C. A., Dunys J., Brau F., Wilk S., Cappai R. Checler F. (2006) 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J. Biol. Chem. 281, 9824 9831.
22. Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524 14529.
23. Dodel R. C., Du Y., Bales K. R., Ling Z., Carvey P. M. Paul S. M. (1999) Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death. Brain Res. Mol. Brain Res. 64, 141 148.
24. Elkon, H., Melamed, E. Offen D. (2004) Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 24, 387 400.
25. Eriksen J. L., Przedborski S. Petrucelli L. (2005) Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 11, 91 96.
26. Farrer M. J. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306 318.
27. Gallo V., Kingsbury A., Balazs R. Jorgensen O. S. (1987) The role of depolarization in the survival and differentiation of cerebellar granule cells in culture. J. Neurosci. 7, 2203 2213.
28. Gandhi S. Wood N. W. (2005) Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 2, 2749 2755.
29. Glinka Y., Gassen M. Youdim M. B. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. Suppl. 50, 55 66.
30. Harrower T. P., Michell A. W. Barker R. A. (2005) Lewy bodies in Parkinson's disease: protectors or perpetrators? Exp. Neurol. 195, 1 6.
31. He Y., Lee T. Leong S. K. (2000) 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. 858, 163 166.
32. Hicke L. (2001) Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2, 195 201.
33. Hirsch E. C., Hoglinger G., Rousselet E., Breidert T., Parain K., Feger J., Ruberg M., Prigent A., Cohen-Salmon C. Launay J. M. (2003) Animal models of Parkinson's disease in rodents induced by toxins: an update. J. Neural Transm. Suppl. 65, 89 100.
34. Hoglinger G. U., Carrard G., Michel P. P., Medja F., Lombes A., Ruberg M., Friguet B. Hirsch E. C. (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86, 1297 1307.
35. Kamp F. Beyer K. (2006) Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J. Biol. Chem. 281, 9251925 9251929.
36. Kaul S., Anantharam V., Kanthasamy A. Kanthasamy A. G. (2005) Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. Brain Res. Mol. Brain Res. 139, 137 152.
37. Kirkpatrick D. S., Hathaway N. A., Hanna J., Elsasser S., Rush J., Finley D., King R. W. Gygi S. P. (2006) Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat. Cell Biol. 8, 700 710.
38. Koh J. Y. Choi D. W. (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Meth. 20, 83 90.
39. Kontopoulos E., Parvin J. D. Feany M. B. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012 3023.
40. Lee M., Hyun D., Halliwell B. Jenner P. (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998 1009.
41. Lee M. K., Stirling W., Xu Y., Xu X., Qui D., Mandir A. S., Dawson T. M., Copeland N. G., Jenkins N. A. Price D. L. (2002) Human alpha-synuclein- harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968 8973.
42. Leng Y. Chuang D. M. (2006) Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26, 7502 7512.
43. Li W. Lee M. K. (2005) Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. J. Neurochem. 93, 1542 1550.
44. Liu S., Ninan I., Antonova I., Battaglia F., Trinchese F., Narasanna A., Kolodilov N., Dauer W., Hawkins R. D. Arancio O. (2004) alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 23, 4506 4516.
45. Lobner D. (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? J. Neurosci. Meth. 96, 147 152.
46. Lowry O. H., Rosenbrough R. J., Farr A. L. Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
47. Madine J., Doig A. J. Middleton D. A. (2006) A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45, 5783 5792.
48. Manning-Bog A. B., McCormack A. L., Purisai M. G., Bolin L. M. Di Monte D. A. (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095 3099.
49. McNaught K. S. Olanow C. W. (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27, 530 545.
50. Meray R. K. Lansbury P. T. Jr. (2007) Reversible monoubiquitination regulates the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282, 10567-10575 Epub ahead of print).
51. Mishizen-Eberz A. J., Norris E. H., Giasson B. I., Hodara R., Ischiropoulos H., Lee V. M., Trojanowski J. Q. Lynch D. R. (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 7818 7829.
52. Morris H. R. (2005) Genetics of Parkinson's disease. Ann. Med. 37, 86 96.
53. Mukaetova-Ladinska E. B. McKeith I. G. (2006) Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127, 188 202.
54. Murphy D. D., Rueter S. M., Trojanowski J. Q. Lee V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214 3220.
55. Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843 9846.
56. Norris E. H., Giasson B. I. Lee V. M. (2004) Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 60, 17 54.
57. Obeso J. A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J. L. Rodriguez-Diaz M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 (1 Suppl. 1 S17 S30.
58. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. Wolozin B. (1999) Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. Neuroscience 19, 5782 5791.
59. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
60. Puttfarcken P. S., Lyons W. E. Coyle J. T. (1992) Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. Neuropharmacology 31, 565 575.
61. Quilty M. C., King A. E., Gai W. P., Pountney D. L., West A. K., Vickers J. C. Dickson T. C. (2006) Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol. 199, 249 256.
62. Rosenberg P. A. (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8, 2887 2894.
63. Saha A. R., Ninkina N. N., Hanger D. P., Anderton B. H., Davies A. M. Buchman V. L. (2000) Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci. 12, 3073 3077.
64. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P. Ebadi M. (2002) Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 24, 143 153.
65. Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318, 215 224.
66. Seo J. H., Rah J. C., Choi S. H. et al. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16, 1826 1828.
67. Shin Y., Klucken J., Patterson C., Hyman B. T. McLean P. J. (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280, 23727 23734.
68. Sidhu A., Wersinger C. Vernier P. (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 18, 637 647.
69. Souza J. M., Giasson B. I., Lee V. M. Ischiropoulos H. (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 11611 11619.
70. Stefanis L., Wang Q., Oo T., Lang-Rollin I., Burke R. E. Dauer W. T. (2004) Lack of alpha-synuclein does not alter apoptosis of neonatal catecholaminergic neurons. Eur. J. Neurosci. 20, 1969 1972.
71. Tabrizi S. J., Orth M., Wilkinson J. M., Taanman J. W., Warner T. T., Cooper J. M. Schapira A. H. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9, 2683 2689.
72. Tofaris G. K. Spillantini M. G. (2005) Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 20 (Suppl. 12 S37 S44.
73. Tofaris G. K., Layfield R. Spillantini M. G. (2001) Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22 26.
74. Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405 44411.
75. Vekrellis K., Rideout H. J. Stefanis L. (2004) Neurobiology of alpha-synuclein. Mol. Neurobiol. 30, 1 21.
76. Wersinger C., Prou D., Vernier P. Sidhu A. (2003a) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151 2153.
77. Wersinger C., Prou D., Vernier P., Niznik H. B. Sidhu A. (2003b) Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol. Cell. Neurosci. 24, 91 105.
78. Withers G. S., George J. M., Banker G. A. Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87 94.
79. Woelk T., Oldrini B., Maspero E., Confalonieri S., Cavallaro E., Di Fiore P. P. Polo S. (2006) Molecular mechanisms of coupled monoubiquitination. Nat. Cell Biol. 8, 1246 1254.
80. Xu S., Zhou M., Yu S., Cai Y., Zhang A., Ueda K. Chan P. (2006) Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun. 342, 330 335.
81. Yamamuro A., Yoshioka Y., Ogita K. Maeda S. (2006) Involvement of endoplasmic reticulum stress on the cell death induced by 6-hydroxydopamine in human neuroblastoma SH-SY5Y cells. Neurochem. Res. 31, 657 664.
82. Zhou W., Hurlbert M. S., Schaack J., Prasad K. N. Freed C. R. (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866, 33 43.